{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:37:03Z","timestamp":1782484623899,"version":"3.54.5"},"reference-count":241,"publisher":"National Institute for Health and Care Research","issue":"64","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["16\/166\/05"],"award-info":[{"award-number":["16\/166\/05"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n Malignant melanoma is the fifth most common cancer in the UK, with rates continuing to rise, resulting in considerable burden to patients and the NHS.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n The objectives were to evaluate the effectiveness and cost-effectiveness of current and alternative follow-up strategies for stage IA and IB melanoma.<\/jats:p>\n <\/jats:sec>\n \n Review methods<\/jats:title>\n Three systematic reviews were conducted. (1) The effectiveness of surveillance strategies. Outcomes were detection of new primaries, recurrences, metastases and survival. Risk of bias was assessed using the Cochrane Collaboration\u2019s Risk-of-Bias 2.0 tool. (2) Prediction models to stratify by risk of recurrence, metastases and survival. Model performance was assessed by study-reported measures of discrimination (e.g. D-statistic, Harrel\u2019s c<\/jats:italic>-statistic), calibration (e.g. the Hosmer\u2013Lemeshow \u2018goodness-of-fit\u2019 test) or overall performance (e.g. Brier score, R<\/jats:italic>\n 2<\/jats:sup>). Risk of bias was assessed using the Prediction model Risk Of Bias ASsessment Tool (PROBAST). (3) Diagnostic test accuracy of fine-needle biopsy and ultrasonography. Outcomes were detection of new primaries, recurrences, metastases and overall survival. Risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies\u20132 (QUADAS\u20132) tool. Review data and data from elsewhere were used to model the cost-effectiveness of alternative surveillance strategies and the value of further research.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n (1) The surveillance review included one randomised controlled trial. There was no evidence of a difference in new primary or recurrence detected (risk ratio 0.75, 95% confidence interval 0.43 to 1.31). Risk of bias was considered to be of some concern. Certainty of the evidence was low. (2) Eleven risk prediction models were identified. Discrimination measures were reported for six models, with the area under the operating curve ranging from 0.59 to 0.88. Three models reported calibration measures, with coefficients of \u2265\u20090.88. Overall performance was reported by two models. In one, the Brier score was slightly better than the American Joint Committee on Cancer scheme score. The other reported an R<\/jats:italic>\n 2<\/jats:sup> of 0.47 (95% confidence interval 0.45 to 0.49). All studies were judged to have a high risk of bias. (3) The diagnostic test accuracy review identified two studies. One study considered fine-needle biopsy and the other considered ultrasonography. The sensitivity and specificity for fine-needle biopsy were 0.94 (95% confidence interval 0.90 to 0.97) and 0.95 (95% confidence interval 0.90 to 0.97), respectively. For ultrasonography, sensitivity and specificity were 1.00 (95% confidence interval 0.03 to 1.00) and 0.99 (95% confidence interval 0.96 to 0.99), respectively. For the reference standards and flow and timing domains, the risk of bias was rated as being high for both studies. The cost-effectiveness results suggest that, over a lifetime, less intensive surveillance than recommended by the National Institute for Health and Care Excellence might be worthwhile. There was considerable uncertainty. Improving the diagnostic performance of cancer nurse specialists and introducing a risk prediction tool could be promising. Further research on transition probabilities between different stages of melanoma and on improving diagnostic accuracy would be of most value.<\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n Overall, few data of limited quality were available, and these related to earlier versions of the American Joint Committee on Cancer staging. Consequently, there was considerable uncertainty in the economic evaluation.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Despite adoption of rigorous methods, too few data are available to justify changes to the National Institute for Health and Care Excellence recommendations on surveillance. However, alternative strategies warrant further research, specifically on improving estimates of incidence, progression of recurrent disease; diagnostic accuracy and health-related quality of life; developing and evaluating risk stratification tools; and understanding patient preferences.<\/jats:p>\n <\/jats:sec>\n \n Study registration<\/jats:title>\n This study is registered as PROSPERO CRD42018086784.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n This project was funded by the National Institute for Health Research Health Technology Assessment programme and will be published in full in Health Technology Assessment<\/jats:italic>; Vol 25, No. 64. See the NIHR Journals Library website for further project information.<\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/hta25640","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T11:07:49Z","timestamp":1637233669000},"page":"1-178","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Optimal surveillance strategies for patients with stage 1 cutaneous melanoma post primary tumour excision: three systematic reviews and an economic model"],"prefix":"10.3310","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8574-8429","authenticated-orcid":true,"given":"Luke","family":"Vale","sequence":"first","affiliation":[{"name":"Institute of Health & Society, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6193-1365","authenticated-orcid":true,"given":"Patience","family":"Kunonga","sequence":"additional","affiliation":[{"name":"Institute of Health & Society, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5348-3750","authenticated-orcid":true,"given":"Diarmuid","family":"Coughlan","sequence":"additional","affiliation":[{"name":"Institute of Health & Society, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9823-992X","authenticated-orcid":true,"given":"Vasileios","family":"Kontogiannis","sequence":"additional","affiliation":[{"name":"Institute of Health & Society, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3482-5567","authenticated-orcid":true,"given":"Margaret","family":"Astin","sequence":"additional","affiliation":[{"name":"Institute of Health & Society, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6396-3467","authenticated-orcid":true,"given":"Fiona","family":"Beyer","sequence":"additional","affiliation":[{"name":"Institute of Health & Society, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2940-5197","authenticated-orcid":true,"given":"Catherine","family":"Richmond","sequence":"additional","affiliation":[{"name":"Institute of Health & Society, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3034-001X","authenticated-orcid":true,"given":"Dor","family":"Wilson","sequence":"additional","affiliation":[{"name":"Institute of Health & Society, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0965-7012","authenticated-orcid":true,"given":"Dalvir","family":"Bajwa","sequence":"additional","affiliation":[{"name":"Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8661-8439","authenticated-orcid":true,"given":"Mehdi","family":"Javanbakht","sequence":"additional","affiliation":[{"name":"Institute of Health & Society, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4351-8865","authenticated-orcid":true,"given":"Andrew","family":"Bryant","sequence":"additional","affiliation":[{"name":"Institute of Health & Society, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9291-3816","authenticated-orcid":true,"given":"Wanwuri","family":"Akor","sequence":"additional","affiliation":[{"name":"Northumbria Healthcare NHS Foundation Trust, North Shields, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5808-0096","authenticated-orcid":true,"given":"Dawn","family":"Craig","sequence":"additional","affiliation":[{"name":"Institute of Health & Society, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6657-6825","authenticated-orcid":true,"given":"Penny","family":"Lovat","sequence":"additional","affiliation":[{"name":"Institute of Translation and Clinical Studies, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8339-7423","authenticated-orcid":true,"given":"Marie","family":"Labus","sequence":"additional","affiliation":[{"name":"Business Development and Enterprise, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4670-0171","authenticated-orcid":true,"given":"Batoul","family":"Nasr","sequence":"additional","affiliation":[{"name":"Dermatological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6081-5891","authenticated-orcid":true,"given":"Timothy","family":"Cunliffe","sequence":"additional","affiliation":[{"name":"Dermatology Department, James Cook University Hospital, Middlesbrough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0057-6758","authenticated-orcid":true,"given":"Helena","family":"Hinde","sequence":"additional","affiliation":[{"name":"Dermatology Department, James Cook University Hospital, Middlesbrough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1021-8439","authenticated-orcid":true,"given":"Mohamed","family":"Shawgi","sequence":"additional","affiliation":[{"name":"Radiology Department, James Cook University Hospital, Middlesbrough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4849-6933","authenticated-orcid":true,"given":"Daniel","family":"Saleh","sequence":"additional","affiliation":[{"name":"Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK"},{"name":"Princess Alexandra Hospital Southside Clinical Unit, Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8033-6556","authenticated-orcid":true,"given":"Pam","family":"Royle","sequence":"additional","affiliation":[{"name":"Patient representative, ITV Tyne Tees, Gateshead, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5460-231X","authenticated-orcid":true,"given":"Paul","family":"Steward","sequence":"additional","affiliation":[{"name":"Patient representative, Dermatology Department, James Cook University Hospital, Middlesbrough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3612-6495","authenticated-orcid":true,"given":"Rachel","family":"Lucas","sequence":"additional","affiliation":[{"name":"Patient representative, Dermatology Department, James Cook University Hospital, Middlesbrough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6305-2121","authenticated-orcid":true,"given":"Robert","family":"Ellis","sequence":"additional","affiliation":[{"name":"Institute of Translation and Clinical Studies, Newcastle University, Newcastle upon Tyne, UK"},{"name":"South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2021,11]]},"reference":[{"key":"key20211117145015979_ref1-bib1","volume-title":"Cutaneous Melanoma: Etiology and Therapy","author":"Matthews","year":"2017"},{"key":"key20211117145015979_ref1-bib2","volume-title":"Cancer Facts and Figures 2018","author":"American Cancer Society"},{"key":"key20211117145015979_ref1-bib3","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials","volume":"26","author":"Korn","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20211117145015979_ref1-bib4","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"key20211117145015979_ref1-bib5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.canep.2016.02.005","article-title":"The burden of cutaneous melanoma and status of preventive measures in Central and South America","volume":"44","author":"de Vries","year":"2016","journal-title":"Cancer Epidemiol"},{"key":"key20211117145015979_ref1-bib6","volume-title":"Skin Cancer Statistics","author":"World Cancer Research Fund International","year":"2018"},{"key":"key20211117145015979_ref1-bib7","volume-title":"Skin Cancer: Risks and Causes","author":"Cancer Research","year":"2017"},{"key":"key20211117145015979_ref1-bib8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1089\/jayao.2016.0074","article-title":"Small numbers, big challenges: adolescent and young adult cancer incidence and survival in New Zealand","volume":"6","author":"Ballantine","year":"2017","journal-title":"J Adolesc Young Adult Oncol"},{"key":"key20211117145015979_ref1-bib9","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.ypmed.2016.08.032","article-title":"Melanoma burden and recent trends among non-Hispanic whites aged 15\u201349 years, United States","volume":"91","author":"Watson","year":"2016","journal-title":"Prev Med"},{"key":"key20211117145015979_ref1-bib10","volume-title":"Melanoma Skin Cancer Incidence Statistics","author":"Cancer Research UK","year":"2019"},{"key":"key20211117145015979_ref1-bib11","volume-title":"Cancer Today","author":"International Agency for Research on Cancer","year":"2018"},{"key":"key20211117145015979_ref1-bib12","volume-title":"Facts About Melanoma and Other Skin Cancers","author":"Miiskin","year":"2019"},{"key":"key20211117145015979_ref1-bib13","volume-title":"Melanoma \u2013 The Facts","author":"Melanoma Patient Network Europe","year":"2013"},{"key":"key20211117145015979_ref1-bib14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.pathol.2017.09.002","article-title":"Trajectories of premalignancy during the journey from melanocyte to melanoma","volume":"50","author":"Colebatch","year":"2018","journal-title":"Pathology"},{"key":"key20211117145015979_ref1-bib15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMra052166","article-title":"Melanoma","volume":"355","author":"Miller","year":"2006","journal-title":"N Engl J Med"},{"key":"key20211117145015979_ref1-bib16","volume-title":"Melanoma: Assessment and Management","author":"National Institute for Health and Care Excellence","year":"2015"},{"key":"key20211117145015979_ref1-bib17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2147\/PROM.S69351","article-title":"Improving outcomes in patients with melanoma: strategies to ensure an early diagnosis","volume":"6","author":"Voss","year":"2015","journal-title":"Patient Relat Outcome Meas"},{"key":"key20211117145015979_ref1-bib18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/bjd.13403","article-title":"Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: a systematic review","volume":"172","author":"Watts","year":"2015","journal-title":"Br J Dermatol"},{"key":"key20211117145015979_ref1-bib19","unstructured":"American Joint Committee on Cancer. AJCC Cancer Staging Manual. 8th edn. Chicago, IL: American Joint Committee on Cancer\/Springer; 2016."},{"key":"key20211117145015979_ref1-bib20","unstructured":"American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th edn. Chicago, IL: American Joint Committee on Cancer; 2010."},{"key":"key20211117145015979_ref1-bib21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jdermsci.2017.01.013","article-title":"Dermoscopic features predicting the presence of mitoses in thin melanoma","volume":"86","author":"Ribero","year":"2017","journal-title":"J Dermatol Sci"},{"key":"key20211117145015979_ref1-bib22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/CLEP.S99021","article-title":"Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe \u2013 a systematic review of the literature","volume":"8","author":"Svedman","year":"2016","journal-title":"Clin Epidemiol"},{"key":"key20211117145015979_ref1-bib23","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1245\/s10434-016-5263-7","article-title":"The MELFO-Study: prospective, randomized, clinical trial for the evaluation of a stage-adjusted reduced follow-up schedule in cutaneous melanoma patients-results after 1 year","volume":"23","author":"Damude","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"key20211117145015979_ref1-bib24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/sj.bjc.6600428","article-title":"Primary staging and follow-up in melanoma patients \u2013 monocenter evaluation of methods, costs and patient survival","volume":"87","author":"Hofmann","year":"2002","journal-title":"Br J Cancer"},{"key":"key20211117145015979_ref1-bib25","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/CMR.0b013e328357d796","article-title":"Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review","volume":"22","author":"Cromwell","year":"2012","journal-title":"Melanoma Res"},{"key":"key20211117145015979_ref1-bib26","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.bjps.2010.07.006","article-title":"Revised UK guidelines for the management of cutaneous melanoma 2010","volume":"63","author":"Marsden","year":"2010","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"key20211117145015979_ref1-bib27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/j.1365-2133.2010.09883.x","article-title":"Revised U.K. guidelines for the management of cutaneous melanoma 2010","volume":"163","author":"Marsden","year":"2010","journal-title":"Br J Dermatol"},{"key":"key20211117145015979_ref1-bib28","first-page":"13","article-title":"Diagnostic and prognostic biomarkers in melanoma","volume":"7","author":"Weinstein","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"key":"key20211117145015979_ref1-bib29","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/0959-8049(95)00087-9","article-title":"Clinical significance of serum S100 in metastatic malignant melanoma","volume":"31","author":"Guo","year":"1995","journal-title":"Eur J Cancer"},{"key":"key20211117145015979_ref1-bib30","volume-title":"The Current Role of Sentinel Lymph Node Biopsy in the Management of Cutaneous Melanoma \u2013 a UK Consensus Statement","author":"Melanoma Focus","year":"2019"},{"key":"key20211117145015979_ref1-bib31","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.1200\/JCO.2005.05.5152","article-title":"Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020","volume":"24","author":"Cornett","year":"2006","journal-title":"J Clin Oncol"},{"key":"key20211117145015979_ref1-bib32","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1245\/s10434-017-5803-9","article-title":"Isolated limb perfusion for melanoma is safe and effective in elderly patients","volume":"24","author":"Madu","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"key20211117145015979_ref1-bib33","first-page":"1045","article-title":"Isolated limb perfusion for stage III melanoma: does it still have a role in the present era of effective systemic therapy?","volume":"30","author":"Gr\u00fcnhagen","year":"2016","journal-title":"Oncology"},{"key":"key20211117145015979_ref1-bib34","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/1754-9485.12536","article-title":"Clinical review of treatment outcomes and patterns of failure with adjuvant radiotherapy in node-positive malignant melanoma","volume":"61","author":"Keenan","year":"2017","journal-title":"J Med Imaging Radiat Oncol"},{"key":"key20211117145015979_ref1-bib35","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/jso.24273","article-title":"Weighing the value of completion nodal dissection for melanoma","volume":"114","author":"Liu","year":"2016","journal-title":"J Surg Oncol"},{"key":"key20211117145015979_ref1-bib36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11912-017-0575-8","article-title":"The role of surgery for melanoma in an era of effective systemic therapy","volume":"19","author":"Raigani","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"key20211117145015979_ref1-bib37","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20211117145015979_ref1-bib38","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"key20211117145015979_ref1-bib39","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"key20211117145015979_ref1-bib40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"key20211117145015979_ref1-bib41","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20211117145015979_ref1-bib42","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"key20211117145015979_ref1-bib43","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"key20211117145015979_ref1-bib44","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"key20211117145015979_ref1-bib45","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"key20211117145015979_ref1-bib46","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"key20211117145015979_ref1-bib47","volume-title":"NICE Pathways \u2013 Melanoma Overview","author":"National Institute for Health and Care Excellence","year":"2019"},{"key":"key20211117145015979_ref1-bib48","doi-asserted-by":"publisher","first-page":"442","DOI":"10.2174\/1568009617666170208163714","article-title":"Melanoma adjuvant treatment: current insight and clinical features","volume":"18","author":"D\u2019Aniello","year":"2018","journal-title":"Curr Cancer Drug Targets"},{"key":"key20211117145015979_ref1-bib49","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/pubmed\/fdt032","article-title":"Measuring current and future cost of skin cancer in England","volume":"36","author":"Vallejo-Torres","year":"2014","journal-title":"J Public Health"},{"key":"key20211117145015979_ref1-bib50","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/pon.3060","article-title":"Psychosocial aspects of post-treatment follow-up for stage I\/II melanoma: a systematic review of the literature (provisional abstract)","volume":"22","author":"Rychetnik","year":"2013","journal-title":"Psycho-Oncology"},{"key":"key20211117145015979_ref1-bib51","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jclinepi.2010.07.001","article-title":"AGREE II: advancing guideline development, reporting and evaluation in health care","volume":"63","author":"Brouwers","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"key20211117145015979_ref1-bib52","volume-title":"AGREE Enterprise Website","author":"Appraisal of Guidelines for Research and Evaluation (AGREE) Research Trust","year":"2014"},{"key":"key20211117145015979_ref1-bib53","volume-title":"Clinical Practice Guidelines for the Diagnosis and Management of Melanoma","author":"Barbour","year":"2018"},{"key":"key20211117145015979_ref1-bib54","volume-title":"Surveillance Proposal Consultation Document: 2019 Surveillance of Melanoma (NICE Guidelines NG14 and CSG8)","author":"National Institute for Health and Care Excellence","year":"2019"},{"key":"key20211117145015979_ref1-bib55","volume-title":"Cutaneous Melanoma","author":"National Comprehensive Cancer Network","year":"2019"},{"key":"key20211117145015979_ref1-bib56","doi-asserted-by":"publisher","first-page":"v126","DOI":"10.1093\/annonc\/mdv297","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Dummer","year":"2015","journal-title":"Ann Oncol"},{"key":"key20211117145015979_ref1-bib57","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","article-title":"Guidelines of care for the management of primary cutaneous melanoma","volume":"80","author":"Swetter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"key20211117145015979_ref1-bib58","volume-title":"Melanoma Guideline 2012","author":"Dutch Working Group on Melanoma","year":"2013"},{"key":"key20211117145015979_ref1-bib59","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/ddg.12044","article-title":"S3-guideline \u2018diagnosis, therapy and follow-up of melanoma\u2019 \u2013 short version","volume":"11","author":"Pflugfelder","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"key":"key20211117145015979_ref1-bib60","doi-asserted-by":"publisher","first-page":"w14279","DOI":"10.4414\/smw.2016.14279","article-title":"The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma","volume":"146","author":"Dummer","year":"2016","journal-title":"Swiss Med Wkly"},{"key":"key20211117145015979_ref1-bib61","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1590\/abd1806-4841.20164715","article-title":"Brazilian guidelines for diagnosis, treatment and follow-up of primary cutaneous melanoma \u2013 Part II","volume":"91","author":"Castro","year":"2016","journal-title":"An Bras Dermatol"},{"key":"key20211117145015979_ref1-bib62","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1046\/j.1365-2133.2003.05241.x","article-title":"The British Association of Dermatologists therapeutic guidelines: can we AGREE?","volume":"148","author":"Cox","year":"2003","journal-title":"Br J Dermatol"},{"key":"key20211117145015979_ref1-bib63","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1365-2133.2008.08641.x","article-title":"An evidence base for reconsidering current follow-up guidelines for patients with cutaneous melanoma less than 0.5\u2009mm thick at diagnosis","volume":"159","author":"Einwachter-Thompson","year":"2008","journal-title":"Br J Dermatol"},{"key":"key20211117145015979_ref1-bib64","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1046\/j.1365-2133.1999.3029a.x","article-title":"The British Association of Dermatologists guidelines for the management of skin disease","volume":"141","author":"Griffiths","year":"1999","journal-title":"Br J Dermatol"},{"key":"key20211117145015979_ref1-bib65","volume-title":"About the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae)","author":"National Comprehensive Cancer Network"},{"key":"key20211117145015979_ref1-bib66","volume-title":"NCCN Categories of Evidence and Consensus","author":"National Comprehensive Cancer Network"},{"key":"key20211117145015979_ref1-bib67","volume-title":"ESMO Clinical Practice Guidelines: Melanoma","author":"ESMO"},{"key":"key20211117145015979_ref1-bib68","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"},{"key":"key20211117145015979_ref1-bib69","volume-title":"Standard Operating Procedures (SOPs) Instructions for Authors and Templates for Standard ESMO Clinical Practice Guidelines (CPGs) and ESMO-MCBS Scores","author":"ESMO Guidelines Committee","year":"2019"},{"key":"key20211117145015979_ref1-bib70","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3122\/jabfm.17.1.59","article-title":"Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature","volume":"17","author":"Ebell","year":"2004","journal-title":"J Am Board Fam Pract"},{"key":"key20211117145015979_ref1-bib71","volume-title":"Cancer Survivorship Care","author":"Association of Community Cancer Centers","year":"2011"},{"key":"key20211117145015979_ref1-bib72","volume-title":"Cancer Screening for Psychosocial Distress","author":"Association of Community Cancer Centers","year":"2011"},{"key":"key20211117145015979_ref1-bib73","volume-title":"S3-Leitlinie zur Diagnostik, Therapie and Nachsorge des Melanoms","author":"German Guideline Program in Oncology","year":"2018"},{"key":"key20211117145015979_ref1-bib74","volume-title":"SIGN 50: A Guideline Developer\u2019s Handbook","author":"Scottish Intercollegiate Guidelines Network","year":"2015"},{"key":"key20211117145015979_ref1-bib75","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1001\/jama.1993.03510170083036","article-title":"Users\u2019 guides to the medical literature. I. How to get started. The Evidence-Based Medicine Working Group","volume":"270","author":"Oxman","year":"1993","journal-title":"JAMA"},{"key":"key20211117145015979_ref1-bib76","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/S1470-2045(05)70283-7","article-title":"Follow-up in patients with localised primary cutaneous melanoma","volume":"6","author":"Francken","year":"2005","journal-title":"Lancet Oncol"},{"key":"key20211117145015979_ref1-bib77","volume-title":"Melanoma: Assessment and Management. 1.9 Follow-up After Treatment for Melanoma","author":"National Institute for Health and Care Excellence","year":"2015"},{"key":"key20211117145015979_ref1-bib78","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred Reporting Items for Systematic reviews and Meta-Analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"key20211117145015979_ref1-bib79","volume-title":"Optimal Surveillance Strategies for AJCC Stage I Cutaneous Melanoma Post Primary Tumour Excision: An Evidence Synthesis and Economic Evaluation","author":"Javanbakht","year":"2019"},{"key":"key20211117145015979_ref1-bib80","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jclinepi.2009.03.008","article-title":"AHRQ series paper 3: identifying, selecting, and refining topics for comparative effectiveness systematic reviews: AHRQ and the effective health-care program","volume":"63","author":"Whitlock","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"key20211117145015979_ref1-bib81","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"key20211117145015979_ref1-bib82","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 [updated September 2020]","author":"Higgins","year":"2020"},{"key":"key20211117145015979_ref1-bib83","first-page":"29","volume-title":"Cochrane Methods. Cochrane Database of Systematic Reviews 2016, Issue 10 (Suppl 1)","author":"Higgins","year":"2016"},{"key":"key20211117145015979_ref1-bib84","volume-title":"GRADEpro GDT: GRADEpro Guideline Development Tool","author":"McMaster University, Evidence Prime Inc"},{"key":"key20211117145015979_ref1-bib85","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamadermatol.2016.1985","article-title":"Early detection of new melanomas by patients with melanoma and their partners using a structured skin self-examination skills training intervention: a randomized clinical trial","volume":"152","author":"Robinson","year":"2016","journal-title":"JAMA Dermatol"},{"key":"key20211117145015979_ref1-bib86","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.2196\/jmir.2883","article-title":"Skin self-examination education for early detection of melanoma: a randomized controlled trial of Internet, workbook, and in-person interventions","volume":"16","author":"Robinson","year":"2014","journal-title":"J Med Internet Res"},{"key":"key20211117145015979_ref1-bib87","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1001\/jamadermatol.2015.0690","article-title":"Comparison of efficacy of differing partner-assisted skin examination interventions for melanoma patients: a randomized clinical trial","volume":"151","author":"Turrisi","year":"2015","journal-title":"JAMA Dermatol"},{"key":"key20211117145015979_ref1-bib88","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1245\/s10434-019-07825-7","article-title":"The MELFO-Study: a multi-center prospective randomized clinical trial on the effects of a reduced stage-adjusted follow-up schedule on cutaneous melanoma IB\u2013IIC patients: results after 3-years","volume":"25","author":"Deckers","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"key20211117145015979_ref1-bib89","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/heartjnl-2011-301247","article-title":"Risk prediction models: II. External validation, model updating, and impact assessment","volume":"98","author":"Moons","year":"2012","journal-title":"Heart"},{"key":"key20211117145015979_ref1-bib90","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20211117145015979_ref1-bib91","doi-asserted-by":"publisher","first-page":"h5940","DOI":"10.1136\/bmj.h5940","article-title":"Sentinel lymph node biopsy in melanoma","volume":"351","author":"Bigby","year":"2015","journal-title":"BMJ"},{"key":"key20211117145015979_ref1-bib92","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000484892","article-title":"Sentinel node biopsy in melanoma: a short update","volume":"5","author":"Ferrara","year":"2018","journal-title":"Dermatopathology"},{"key":"key20211117145015979_ref1-bib93","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2214\/AJR.15.15182","article-title":"Assessment of cutaneous melanoma by use of very high-frequency ultrasound and real-time elastography","volume":"206","author":"Botar-Jid","year":"2016","journal-title":"AJR Am J Roentgenol"},{"key":"key20211117145015979_ref1-bib94","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40425-018-0397-8","article-title":"The age of enlightenment in melanoma immunotherapy","volume":"6","author":"Albertini","year":"2018","journal-title":"J Immunother Cancer"},{"key":"key20211117145015979_ref1-bib95","doi-asserted-by":"publisher","first-page":"61","DOI":"10.5114\/wo.2018.73889","article-title":"Immunotherapy of melanoma","volume":"22","author":"Lugowska","year":"2018","journal-title":"Contemp Oncol"},{"key":"key20211117145015979_ref1-bib96","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.4103\/jcrt.JCRT_1290_16","article-title":"Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma","volume":"14","author":"Koppolu","year":"2018","journal-title":"J Cancer Res Ther"},{"key":"key20211117145015979_ref1-bib97","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1158\/1055-9965.EPI-14-0295","article-title":"Risk prediction models for melanoma: a systematic review","volume":"23","author":"Usher-Smith","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key20211117145015979_ref1-bib98","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1001\/jamadermatol.2013.8890","article-title":"Risk prediction models for incident primary cutaneous melanoma: a systematic review","volume":"150","author":"Vuong","year":"2014","journal-title":"JAMA Dermatol"},{"key":"key20211117145015979_ref1-bib99","doi-asserted-by":"publisher","first-page":"e32844","DOI":"10.1371\/journal.pone.0032844","article-title":"Search filters for finding prognostic and diagnostic prediction studies in Medline to enhance systematic reviews","volume":"7","author":"Geersing","year":"2012","journal-title":"PLOS ONE"},{"key":"key20211117145015979_ref1-bib100","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.bjps.2017.05.025","article-title":"Sentinel node biopsy status is strongly predictive of survival in cutaneous melanoma: extended follow-up of Oxford patients from 1998 to 2014","volume":"70","author":"Thomson","year":"2017","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"key20211117145015979_ref1-bib101","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-77244-8","volume-title":"Clinical Prediction Models","author":"Steyerberg","year":"2009"},{"key":"key20211117145015979_ref1-bib102","doi-asserted-by":"publisher","first-page":"e1001744","DOI":"10.1371\/journal.pmed.1001744","article-title":"Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist","volume":"11","author":"Moons","year":"2014","journal-title":"PLOS Med"},{"key":"key20211117145015979_ref1-bib103","doi-asserted-by":"publisher","first-page":"51","DOI":"10.7326\/M18-1376","article-title":"PROBAST: a tool to assess the risk of bias and applicability of prediction model studies (Prediction model Risk Of Bias ASsessment Tool)","volume":"170","author":"Wolff","year":"2019","journal-title":"Ann Intern Med"},{"key":"key20211117145015979_ref1-bib104","doi-asserted-by":"publisher","first-page":"h870","DOI":"10.1136\/bmj.h870","article-title":"Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients","volume":"350","author":"Iorio","year":"2015","journal-title":"BMJ"},{"key":"key20211117145015979_ref1-bib105","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12885-015-1024-4","article-title":"Prognostic survival model for people diagnosed with invasive cutaneous melanoma","volume":"15","author":"Baade","year":"2015","journal-title":"BMC Cancer"},{"key":"key20211117145015979_ref1-bib106","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":"Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"key":"key20211117145015979_ref1-bib107","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0046-8177(00)80246-4","article-title":"Individualized prognosis for melanoma patients","volume":"31","author":"Cochran","year":"2000","journal-title":"Hum Pathol"},{"key":"key20211117145015979_ref1-bib108","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1200\/JCO.2006.08.1463","article-title":"Identification of high-risk patients among those diagnosed with thin cutaneous melanomas","volume":"25","author":"Gimotty","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20211117145015979_ref1-bib109","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1200\/JCO.2004.12.015","article-title":"Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging","volume":"22","author":"Gimotty","year":"2004","journal-title":"J Clin Oncol"},{"key":"key20211117145015979_ref1-bib110","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1200\/JCO.2013.54.2340","article-title":"Prediction of survival in patients with thin melanoma: results from a multi-institution study","volume":"32","author":"Maurichi","year":"2014","journal-title":"J Clin Oncol"},{"key":"key20211117145015979_ref1-bib111","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/modpathol.2017.64","article-title":"Computer-assisted measurement of primary tumor area is prognostic of recurrence-free survival in stage IB melanoma patients","volume":"30","author":"Rosenbaum","year":"2017","journal-title":"Mod Pathol"},{"key":"key20211117145015979_ref1-bib112","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/PAS.0000000000001034","article-title":"Breslow density is a novel prognostic feature that adds value to melanoma staging","volume":"42","author":"Saldanha","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"key20211117145015979_ref1-bib113","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1245\/s10434-010-1050-z","article-title":"Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database","volume":"17","author":"Soong","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"key20211117145015979_ref1-bib114","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/10543400701199585","article-title":"An integrated tree-based classification approach to prognostic grouping with application to localized melanoma patients","volume":"17","author":"Tsai","year":"2007","journal-title":"J Biopharm Stat"},{"key":"key20211117145015979_ref1-bib115","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1309\/WAVR-560R-NU5E-4Q96","article-title":"Using a continuous transformation of the Breslow thickness for prognosis in cutaneous melanoma","volume":"115","author":"Vollmer","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"key20211117145015979_ref1-bib116","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/biomet\/92.4.965","article-title":"Concordance probability and discriminatory power in proportional hazards regression","volume":"92","author":"G\u00f6nen","year":"2005","journal-title":"Biometrika"},{"key":"key20211117145015979_ref1-bib117","first-page":"11","volume-title":"Cutaneous Melanoma","author":"Stadelmann","year":"1998","edition":"3rd"},{"key":"key20211117145015979_ref1-bib118","volume-title":"Model Selection and Multi-model Inference: A Practical Information-Theoretic Approach","author":"Burnham","year":"2002","edition":"2nd"},{"key":"key20211117145015979_ref1-bib119","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/bmjqs-2015-004278","article-title":"Making sense of the shadows: priorities for creating a learning healthcare system based on routinely collected data","volume":"24","author":"Deeny","year":"2015","journal-title":"BMJ Qual Saf"},{"key":"key20211117145015979_ref1-bib120","doi-asserted-by":"publisher","first-page":"W1","DOI":"10.7326\/M18-1377","article-title":"PROBAST: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration","volume":"170","author":"Moons","year":"2019","journal-title":"Ann Intern Med"},{"key":"key20211117145015979_ref1-bib121","doi-asserted-by":"publisher","first-page":"S574","DOI":"10.21037\/jtd.2019.01.25","article-title":"Developing prediction models for clinical use using logistic regression: an overview","volume":"11","author":"Shipe","year":"2019","journal-title":"J Thorac Dis"},{"key":"key20211117145015979_ref1-bib122","doi-asserted-by":"publisher","first-page":"i3140","DOI":"10.1136\/bmj.i3140","article-title":"External validation of clinical prediction models using big datasets from e-health records or IPD meta-analysis: opportunities and challenges","volume":"353","author":"Riley","year":"2016","journal-title":"BMJ"},{"key":"key20211117145015979_ref1-bib123","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1002\/sim.6080","article-title":"Meta-analysis and aggregation of multiple published prediction models","volume":"33","author":"Debray","year":"2014","journal-title":"Stat Med"},{"key":"key20211117145015979_ref1-bib124","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","article-title":"Assessing the performance of prediction models: a framework for traditional and novel measures","volume":"21","author":"Steyerberg","year":"2010","journal-title":"Epidemiology"},{"key":"key20211117145015979_ref1-bib125","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/sim.1621","article-title":"A new measure of prognostic separation in survival data","volume":"23","author":"Royston","year":"2004","journal-title":"Stat Med"},{"key":"key20211117145015979_ref1-bib126","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2288-13-33","article-title":"External validation of a Cox prognostic model: principles and methods","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"key20211117145015979_ref1-bib127","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/sim.5941","article-title":"Graphical assessment of internal and external calibration of logistic regression models by using LOESS smoothers","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"key":"key20211117145015979_ref1-bib128","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S0895-4356(01)00341-9","article-title":"Internal validation of predictive models: efficiency of some procedures for logistic regression analysis","volume":"54","author":"Steyerberg","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"key20211117145015979_ref1-bib129","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jclinepi.2014.06.018","article-title":"A new framework to enhance the interpretation of external validation studies of clinical prediction models","volume":"68","author":"Debray","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"key20211117145015979_ref1-bib130","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/jth.12262","article-title":"Diagnostic and prognostic prediction models","volume":"11","author":"Hendriksen","year":"2013","journal-title":"J Thromb Haemost"},{"key":"key20211117145015979_ref1-bib131","doi-asserted-by":"publisher","first-page":"b604","DOI":"10.1136\/bmj.b604","article-title":"Prognosis and prognostic research: developing a prognostic model","volume":"338","author":"Royston","year":"2009","journal-title":"BMJ"},{"key":"key20211117145015979_ref1-bib132","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s41512-017-0020-3","article-title":"The Brier score does not evaluate the clinical utility of diagnostic tests or prediction models","volume":"1","author":"Assel","year":"2017","journal-title":"Diagn Progn Res"},{"key":"key20211117145015979_ref1-bib133","doi-asserted-by":"publisher","first-page":"b605","DOI":"10.1136\/bmj.b605","article-title":"Prognosis and prognostic research: validating a prognostic model","volume":"338","author":"Altman","year":"2009","journal-title":"BMJ"},{"key":"key20211117145015979_ref1-bib134","doi-asserted-by":"publisher","first-page":"b606","DOI":"10.1136\/bmj.b606","article-title":"Prognosis and prognostic research: application and impact of prognostic models in clinical practice","volume":"338","author":"Moons","year":"2009","journal-title":"BMJ"},{"key":"key20211117145015979_ref1-bib135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-014-0241-z","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement","volume":"13","author":"Collins","year":"2015","journal-title":"BMC Med"},{"key":"key20211117145015979_ref1-bib136","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10585-018-9892-z","article-title":"Review of diagnostic, prognostic, and predictive biomarkers in melanoma","volume":"35","author":"Ankeny","year":"2018","journal-title":"Clin Exp Metastasis"},{"key":"key20211117145015979_ref1-bib137","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/jso.25319","article-title":"Identification of risk in cutaneous melanoma patients: Prognostic and predictive markers","volume":"119","author":"Hyams","year":"2019","journal-title":"J Surg Oncol"},{"key":"key20211117145015979_ref1-bib138","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ijsu.2008.03.003","article-title":"Prognostic factors of cutaneous melanoma in relation to metastasis at the sentinel lymph node: a case-controlled study","volume":"6","author":"Sartore","year":"2008","journal-title":"Int J Surg"},{"key":"key20211117145015979_ref1-bib139","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1136\/bmj.38849.680509.AE","article-title":"Value of sentinel node status as a prognostic factor in melanoma: prospective observational study","volume":"332","author":"Kettlewell","year":"2006","journal-title":"BMJ"},{"key":"key20211117145015979_ref1-bib140","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1067\/j.cpradiol.2009.04.001","article-title":"Cutaneous melanoma: role of ultrasound in the assessment of locoregional spread","volume":"39","author":"Catalano","year":"2010","journal-title":"Curr Probl Diagn Radiol"},{"key":"key20211117145015979_ref1-bib141","doi-asserted-by":"publisher","first-page":"4994","DOI":"10.1200\/JCO.2008.19.0033","article-title":"Rotterdam criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma?","volume":"27","author":"Voit","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20211117145015979_ref1-bib142","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1200\/JCO.2009.25.7428","article-title":"Ultrasound morphology criteria predict metastatic disease of the sentinel nodes in patients with melanoma","volume":"28","author":"Voit","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20211117145015979_ref1-bib143","first-page":"357","article-title":"Role of high resolution color-Doppler US of the sentinel node in patients with stage I melanoma","volume":"102","author":"Bossi","year":"2001","journal-title":"Radiol Med"},{"key":"key20211117145015979_ref1-bib144","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/00008390-200412000-00015","article-title":"The role of preoperative ultrasonography in reducing the number of sentinel lymph node procedures in melanoma","volume":"14","author":"Hocevar","year":"2004","journal-title":"Melanoma Res"},{"key":"key20211117145015979_ref1-bib145","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1245\/s10434-006-9106-9","article-title":"Ultrasonography and fine-needle aspiration cytology in the preoperative evaluation of melanoma patients eligible for sentinel node biopsy","volume":"13","author":"van Rijk","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"key20211117145015979_ref1-bib146","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1586\/era.11.115","article-title":"New developments in melanoma: utility of ultrasound imaging (initial staging, follow-up and pre-SLNB)","volume":"11","author":"Ulrich","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"key20211117145015979_ref1-bib147","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/jnci\/djq455","article-title":"Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis","volume":"103","author":"Xing","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"key20211117145015979_ref1-bib148","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1309\/AJCPWSDDHLLW40WI","article-title":"Fine-needle aspiration cytology for the diagnosis of metastatic melanoma: systematic review and meta-analysis","volume":"140","author":"Hall","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"key20211117145015979_ref1-bib149","doi-asserted-by":"publisher","first-page":"MR000022","DOI":"10.1002\/14651858.MR000022.pub3","article-title":"Search strategies to identify diagnostic accuracy studies in MEDLINE and EMBASE","volume":"9","author":"Beynon","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"key20211117145015979_ref1-bib150","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1046\/j.1365-2532.2003.00427.x","article-title":"Clinical Evidence diagnosis: Developing a sensitive search strategy to retrieve diagnostic studies on deep vein thrombosis: a pragmatic approach","volume":"20","author":"Vincent","year":"2003","journal-title":"Health Info Libr J"},{"key":"key20211117145015979_ref1-bib151","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/0272989X8700700208","article-title":"Intermediate, indeterminate, and uninterpretable diagnostic test results","volume":"7","author":"Simel","year":"1987","journal-title":"Med Decis Making"},{"key":"key20211117145015979_ref1-bib152","doi-asserted-by":"publisher","first-page":"e012799","DOI":"10.1136\/bmjopen-2016-012799","article-title":"STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration","volume":"6","author":"Cohen","year":"2016","journal-title":"BMJ Open"},{"key":"key20211117145015979_ref1-bib153","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"key20211117145015979_ref1-bib154","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.jclinepi.2005.02.022","article-title":"Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews","volume":"58","author":"Reitsma","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"key20211117145015979_ref1-bib155","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"key20211117145015979_ref1-bib156","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jbi.2014.02.013","article-title":"Sample size estimation in diagnostic test studies of biomedical informatics","volume":"48","author":"Hajian-Tilaki","year":"2014","journal-title":"J Biomed Inform"},{"key":"key20211117145015979_ref1-bib157","doi-asserted-by":"publisher","first-page":"YE01","DOI":"10.7860\/JCDR\/2016\/18129.8744","article-title":"Requirements for minimum sample size for sensitivity and specificity analysis","volume":"10","author":"Bujang","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"key20211117145015979_ref1-bib158","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1556\/OH.2012.29434","article-title":"The importance of fine needle aspiration cytology in the management of recurrent and metastatic melanoma","volume":"153","author":"P\u00e1ncz\u00e9l","year":"2012","journal-title":"Orv Hetil"},{"key":"key20211117145015979_ref1-bib159","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1002\/1097-0142(20000601)88:11<2534::AID-CNCR15>3.0.CO;2-2","article-title":"Ultrasound examination of regional lymph nodes significantly improves early detection of locoregional metastases during the follow-up of patients with cutaneous melanoma: results of a prospective study of 1288 patients","volume":"88","author":"Blum","year":"2000","journal-title":"Cancer"},{"key":"key20211117145015979_ref1-bib160","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1365-2133.2006.07361.x","article-title":"Fine-needle aspiration biopsy with ultrasound guidance in patients with malignant melanoma and palpable lymph nodes","volume":"155","author":"Dalle","year":"2006","journal-title":"Br J Dermatol"},{"key":"key20211117145015979_ref1-bib161","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/bjs.11112","article-title":"Prospective cohort study of ultrasound surveillance of regional lymph nodes in patients with intermediate-risk cutaneous melanoma","volume":"106","author":"Hayes","year":"2019","journal-title":"Br J Surg"},{"key":"key20211117145015979_ref1-bib162","doi-asserted-by":"publisher","first-page":"W8","DOI":"10.2214\/AJR.10.4711","article-title":"Contrast-enhanced ultrasound for characterizing lymph nodes with focal cortical thickening in patients with cutaneous melanoma","volume":"196","author":"Rubaltelli","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"key20211117145015979_ref1-bib163","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1245\/s10434-006-9341-0","article-title":"Diagnostic accuracy of fine needle biopsy for metastatic melanoma and its implications for patient management","volume":"15","author":"Doubrovsky","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"key20211117145015979_ref1-bib164","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/CMR.0b013e328348dad3","article-title":"Lymph node ultrasound during melanoma follow-up significantly improves metastasis detection compared with clinical examination alone: a study on 433 patients","volume":"21","author":"Kr\u00fcger","year":"2011","journal-title":"Melanoma Res"},{"key":"key20211117145015979_ref1-bib165","first-page":"113ff","volume-title":"High resolution sonography of cervical lymph nodes in head and neck cancer: criteria for differentiation of reactive versus malignant lymph nodes","author":"Solbiati"},{"key":"key20211117145015979_ref1-bib166","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1148\/radiology.183.1.1549675","article-title":"Differentiation of benign from malignant superficial lymphadenopathy: the role of high resolution US","volume":"183","author":"Vassallo","year":"1992","journal-title":"Radiology"},{"key":"key20211117145015979_ref1-bib167","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1610-0387.2008.06711.x","article-title":"Short German guidelines: malignant melanoma","volume":"6","author":"Garbe","year":"2008","journal-title":"J Dtsch Dermatol Ges"},{"key":"key20211117145015979_ref1-bib168","doi-asserted-by":"publisher","first-page":"202e","DOI":"10.1097\/PRS.0000000000004571","article-title":"Malignant melanoma: diagnostic and management update","volume":"142","author":"Knackstedt","year":"2018","journal-title":"Plast Reconstr Surg"},{"key":"key20211117145015979_ref1-bib169","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1470-2045(04)01609-2","article-title":"Ultrasonography or palpation for detection of melanoma nodal invasion: a meta-analysis","volume":"5","author":"Bafounta","year":"2004","journal-title":"Lancet Oncol"},{"key":"key20211117145015979_ref1-bib170","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012806.pub2","article-title":"Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma","volume":"7","author":"Dinnes","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"key20211117145015979_ref1-bib171","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/(SICI)1097-0142(19970915)80:6<1052::AID-CNCR7>3.0.CO;2-B","article-title":"Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: a cost-effectiveness analysis","volume":"80","author":"Mooney","year":"1997","journal-title":"Cancer"},{"key":"key20211117145015979_ref1-bib172","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000246546","article-title":"Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France","volume":"191","author":"Bass\u00e8res","year":"1995","journal-title":"Dermatology"},{"key":"key20211117145015979_ref1-bib173","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/j.1610-0387.2007.06454.x","article-title":"Cost-effectiveness of reduced follow-up in malignant melanoma","volume":"5","author":"Hengge","year":"2007","journal-title":"J Dtsch Dermatol Ges"},{"key":"key20211117145015979_ref1-bib174","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1245\/s10434-008-0164-z","article-title":"The cost-effectiveness of sentinel node biopsy in patients with intermediate thickness primary cutaneous melanoma","volume":"16","author":"Morton","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"key20211117145015979_ref1-bib175","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.suronc.2016.05.020","article-title":"Sentinel node biopsy in patients with primary cutaneous melanoma of any thickness: a cost-effectiveness analysis","volume":"25","author":"Serra-Arbeloa","year":"2016","journal-title":"Surg Oncol"},{"key":"key20211117145015979_ref1-bib176","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S0190-9622(99)70010-1","article-title":"Screening for malignant melanoma: a cost-effectiveness analysis","volume":"41","author":"Freedberg","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"key20211117145015979_ref1-bib177","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1001\/archderm.143.1.21","article-title":"Visual screening for malignant melanoma: a cost-effectiveness analysis","volume":"143","author":"Losina","year":"2007","journal-title":"Arch Dermatol"},{"key":"key20211117145015979_ref1-bib178","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3109\/02841860903440254","article-title":"Cost-effectiveness analysis of FDG PET-CT in the management of pulmonary metastases from malignant melanoma","volume":"49","author":"Krug","year":"2010","journal-title":"Acta Oncol"},{"key":"key20211117145015979_ref1-bib179","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1586\/erp.13.22","article-title":"Cost-effectiveness of a FISH assay for the diagnosis of melanoma in the USA","volume":"13","author":"Kansal","year":"2013","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"key20211117145015979_ref1-bib180","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jval.2016.12.017","article-title":"Cost-effectiveness analysis of a skin awareness intervention for early detection of skin cancer targeting men older than 50 years","volume":"20","author":"Gordon","year":"2017","journal-title":"Value Health"},{"key":"key20211117145015979_ref1-bib181","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jss.2017.02.070","article-title":"Surveillance strategies in the follow-up of melanoma patients: too much or not enough?","volume":"214","author":"Kurtz","year":"2017","journal-title":"J Surg Res"},{"key":"key20211117145015979_ref1-bib182","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.jval.2017.11.009","article-title":"A modeling study of the cost-effectiveness of a risk-stratified surveillance program for melanoma in the United Kingdom","volume":"21","author":"Wilson","year":"2018","journal-title":"Value Health"},{"key":"key20211117145015979_ref1-bib183","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jval.2012.12.008","article-title":"The cost-effectiveness of a novel SIAscopic diagnostic aid for the management of pigmented skin lesions in primary care: a decision-analytic model","volume":"16","author":"Wilson","year":"2013","journal-title":"Value Health"},{"issue":"58","key":"key20211117145015979_ref1-bib184","doi-asserted-by":"publisher","DOI":"10.3310\/hta20580","article-title":"VivaScope\u00ae 1500 and 3000 systems for detecting and monitoring skin lesions: a systematic review and economic evaluation","volume":"20","author":"Edwards","year":"2016","journal-title":"Health Technol Assess"},{"key":"key20211117145015979_ref1-bib185","volume-title":"Micro-simulation","author":"York Health Economics Consortium","year":"2016"},{"key":"key20211117145015979_ref1-bib186","volume-title":"Markov Model","author":"York Health Economics Consortium","year":"2016"},{"key":"key20211117145015979_ref1-bib187","volume-title":"Guide to the Methods of Technology Appraisal 2013","author":"National Institute for Health and Care Excellence"},{"key":"key20211117145015979_ref1-bib188","volume-title":"Melanoma Skin Cancer Statistics","author":"Cancer Research UK","year":"2019"},{"key":"key20211117145015979_ref1-bib189","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1097\/SLA.0000000000000233","article-title":"Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies","volume":"259","author":"Rueth","year":"2014","journal-title":"Ann Surg"},{"issue":"36","key":"key20211117145015979_ref1-bib190","doi-asserted-by":"publisher","DOI":"10.3310\/hta8360","article-title":"Review of guidelines for good practice in decision-analytic modelling in health technology assessment","volume":"8","author":"Philips","year":"2004","journal-title":"Health Technol Assess"},{"key":"key20211117145015979_ref1-bib191","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1111\/j.1468-3083.2011.04297.x","article-title":"Melanoma patients receive more follow-up care than current guideline recommendations: a study of 546 patients from the general Dutch population","volume":"26","author":"Holterhues","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key20211117145015979_ref1-bib192","volume-title":"Improving Outcomes for People with Skin Tumours Including Melanoma","author":"National Institute for Health and Care Excellence","year":"2006"},{"key":"key20211117145015979_ref1-bib193","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jval.2017.10.009","article-title":"Expert elicitation of multinomial probabilities for decision-analytic modeling: an application to rates of disease progression in undiagnosed and untreated melanoma","volume":"21","author":"Wilson","year":"2018","journal-title":"Value Health"},{"key":"key20211117145015979_ref1-bib194","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2340\/00015555-2239","article-title":"Validity of ABCD rule of dermoscopy in clinical practice","volume":"96","author":"Ahnlide","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"key20211117145015979_ref1-bib195","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/00008390-200008000-00005","article-title":"Digital epiluminescence microscopy: usefulness in the differential diagnosis of cutaneous pigmentary lesions. A statistical comparison between visual and computer inspection","volume":"10","author":"Bauer","year":"2000","journal-title":"Melanoma Res"},{"key":"key20211117145015979_ref1-bib196","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1034\/j.1600-0846.2002.00335.x","article-title":"The gold standard for photographing pigmented skin lesions for diagnostic purposes: contact versus distant imaging","volume":"8","author":"Carli","year":"2002","journal-title":"Skin Res Technol"},{"key":"key20211117145015979_ref1-bib197","first-page":"599","article-title":"Epiluminescence microscopy reduces the risk of removing clinically atypical, but histologically common, melanocytic lesions","volume":"129","author":"Carli","year":"1994","journal-title":"G Ital Dermatol Venereol"},{"key":"key20211117145015979_ref1-bib198","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/CMR.0b013e32832a1e41","article-title":"Computer versus human diagnosis of melanoma: evaluation of the feasibility of an automated diagnostic system in a prospective clinical trial","volume":"19","author":"Dreiseitl","year":"2009","journal-title":"Melanoma Res"},{"key":"key20211117145015979_ref1-bib199","first-page":"7","article-title":"Dermoscopic and histopathological correlation in melanocytic and non-melanocytic lesions","volume":"21","author":"Gokdemir","year":"2011","journal-title":"Turkiye Klinikleri Dermatoloji"},{"key":"key20211117145015979_ref1-bib200","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.jaad.2009.08.049","article-title":"Seven-point checklist for dermatoscopy: performance during 10 years of prospective surveillance of patients at increased melanoma risk","volume":"62","author":"Haenssle","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"key20211117145015979_ref1-bib201","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S0001-7310(08)74697-0","article-title":"Correlation between clinical, dermatoscopic, and histopathologic variables in atypical melanocytic nevi","volume":"99","author":"Morales-Callaghan","year":"2008","journal-title":"Actas Dermosifiliogr"},{"key":"key20211117145015979_ref1-bib202","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S0190-9622(94)70061-3","article-title":"The ABCD rule of dermatoscopy. High prospective value in the diagnosis of doubtful melanocytic skin lesions","volume":"30","author":"Nachbar","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"key20211117145015979_ref1-bib203","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000246629","article-title":"Diagnostic reliability of dermoscopic criteria for detecting malignant melanoma","volume":"190","author":"Soyer","year":"1995","journal-title":"Dermatology"},{"key":"key20211117145015979_ref1-bib204","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/jid.2008.193","article-title":"In vivo reflectance confocal microscopy enhances secondary evaluation of melanocytic lesions","volume":"129","author":"Guitera","year":"2009","journal-title":"J Invest Dermatol"},{"key":"key20211117145015979_ref1-bib205","first-page":"573","article-title":"Clinical and dermatoscopic diagnosis of small pigmented skin lesions","volume":"12","author":"Bono","year":"2002","journal-title":"Eur J Dermatol"},{"key":"key20211117145015979_ref1-bib206","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1159\/000066436","article-title":"Melanoma detection. A prospective study comparing diagnosis with the naked eye, dermatoscopy and telespectrophotometry","volume":"205","author":"Bono","year":"2002","journal-title":"Dermatology"},{"key":"key20211117145015979_ref1-bib207","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jaad.2015.07.028","article-title":"Computer-aided classification of melanocytic lesions using dermoscopic images","volume":"73","author":"Ferris","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"key20211117145015979_ref1-bib208","doi-asserted-by":"publisher","first-page":"j2813","DOI":"10.1136\/bmj.j2813","article-title":"Pathologists\u2019 diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study","volume":"357","author":"Elmore","year":"2017","journal-title":"BMJ"},{"key":"key20211117145015979_ref1-bib209","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2010.09.772","article-title":"Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry","volume":"66","author":"Leiter","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"key20211117145015979_ref1-bib210","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1200\/JCO.2010.34.2956","article-title":"Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma","volume":"29","author":"Turner","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20211117145015979_ref1-bib211","volume-title":"National Life Tables: UK","author":"Office for National Statistics","year":"2019"},{"key":"key20211117145015979_ref1-bib212","volume-title":"Reference Costs 2017\/18: Highlights, Analysis and Introduction to the Data","author":"Department of Health and Social Care","year":"2018"},{"key":"key20211117145015979_ref1-bib213","volume-title":"Trametinib in Combination with Dabrafenib for Treating Unresectable or Metastatic Melanoma","author":"National Institute for Health and Care Excellence","year":"2016"},{"key":"key20211117145015979_ref1-bib214","volume-title":"Nivolumab in Combination with Ipilimumab for Treating Advanced Melanoma","author":"National Institute for Health and Care Excellence","year":"2016"},{"key":"key20211117145015979_ref1-bib215","volume-title":"British National Formulary","author":"Joint Formulary Committee"},{"key":"key20211117145015979_ref1-bib216","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/bjd.16098","article-title":"A systematic review and meta-analysis of utility estimates in melanoma","volume":"178","author":"Tran","year":"2018","journal-title":"Br J Dermatol"},{"key":"key20211117145015979_ref1-bib217","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jval.2019.01.004","article-title":"Identification, review, and use of health state utilities in cost-effectiveness models: an ISPOR Good Practices for Outcomes Research Task Force Report","volume":"22","author":"Brazier","year":"2019","journal-title":"Value Health"},{"key":"key20211117145015979_ref1-bib218","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J Transl Med"},{"key":"key20211117145015979_ref1-bib219","volume-title":"Nivolumab for Treating Advanced (Unresectable or Metastatic) Melanoma","author":"National institute for Health and Care Excellence","year":"2016"},{"key":"key20211117145015979_ref1-bib220","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/hec.3086","article-title":"The influence of cost-effectiveness and other factors on NICE decisions","volume":"24","author":"Dakin","year":"2015","journal-title":"Health Econ"},{"key":"key20211117145015979_ref1-bib221","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/hec.903","article-title":"Cost-effectiveness acceptability curves \u2013 facts, fallacies and frequently asked questions","volume":"13","author":"Fenwick","year":"2004","journal-title":"Health Econ"},{"key":"key20211117145015979_ref1-bib222","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/978-3-642-59410-6_24","article-title":"A rational approach to the follow-up of melanoma patients","volume":"160","author":"Garbe","year":"2002","journal-title":"Recent Results Cancer Res"},{"key":"key20211117145015979_ref1-bib223","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/00000658-199505000-00014","article-title":"Melanoma recurrence surveillance. Patient or physician based?","volume":"221","author":"Shumate","year":"1995","journal-title":"Ann Surg"},{"key":"key20211117145015979_ref1-bib224","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1245\/s10434-007-9347-2","article-title":"Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines","volume":"14","author":"Francken","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"key20211117145015979_ref1-bib225","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10198-007-0069-y","article-title":"Estimating the expected value of partial perfect information: a review of methods","volume":"9","author":"Coyle","year":"2008","journal-title":"Eur J Health Econ"},{"key":"key20211117145015979_ref1-bib226","volume-title":"Survival by Stage","author":"National Cancer Registration and Analysis Service","year":"2019"},{"key":"key20211117145015979_ref1-bib227","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/0272989X13505910","article-title":"Estimating multiparameter partial expected value of perfect information from a probabilistic sensitivity analysis sample: a nonparametric regression approach","volume":"34","author":"Strong","year":"2014","journal-title":"Med Decis Making"},{"key":"key20211117145015979_ref1-bib228","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2165\/00019053-200017050-00007","article-title":"Testing the validity of cost-effectiveness models","volume":"17","author":"McCabe","year":"2000","journal-title":"PharmacoEconomics"},{"key":"key20211117145015979_ref1-bib229","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015","edition":"4th"},{"key":"key20211117145015979_ref1-bib230","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jval.2015.09.2939","article-title":"Beware of kinked frontiers: a systematic review of the choice of comparator strategies in cost-effectiveness analyses of human papillomavirus testing in cervical screening","volume":"18","author":"O\u2019Mahony","year":"2015","journal-title":"Value Health"},{"key":"key20211117145015979_ref1-bib231","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1001\/jamadermatol.2019.0440","article-title":"Risk of melanoma recurrence after diagnosis of a high-risk primary tumor","volume":"155","author":"von Schuckmann","year":"2019","journal-title":"JAMA Dermatol"},{"key":"key20211117145015979_ref1-bib232","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1111\/bjd.13455","article-title":"Essential inputs for studies of cost-effectiveness analysis in melanoma","volume":"171","author":"Morton","year":"2014","journal-title":"Br J Dermatol"},{"key":"key20211117145015979_ref1-bib233","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1111\/bjd.13262","article-title":"Health-related quality of life in patients with melanoma expressed as utilities and disability weights","volume":"171","author":"Tromme","year":"2014","journal-title":"Br J Dermatol"},{"key":"key20211117145015979_ref1-bib234","volume-title":"GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations","author":"Sch\u00fcnemann","year":"2013"},{"key":"key20211117145015979_ref1-bib235","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jaad.2013.11.038","article-title":"Skin cancer and photoprotection in people of color: a review and recommendations for physicians and the public","volume":"70","author":"Agbai","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"key20211117145015979_ref1-bib236","doi-asserted-by":"publisher","first-page":"a1655","DOI":"10.1136\/bmj.a1655","article-title":"Developing and evaluating complex interventions: the new Medical Research Council guidance","volume":"337","author":"Craig","year":"2008","journal-title":"BMJ"},{"key":"key20211117145015979_ref1-bib237","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/archdermatol.2009.370","article-title":"Selection of patients for long-term surveillance with digital dermoscopy by assessment of melanoma risk factors","volume":"146","author":"Haenssle","year":"2010","journal-title":"Arch Dermatol"},{"key":"key20211117145015979_ref1-bib238","volume-title":"CEA Registry","author":"Tufts Medical Center","year":"2018"},{"key":"key20211117145015979_ref1-bib239","volume-title":"HERC Database of Mapping Studies","author":"Health Economics Research Centre","year":"2019"},{"key":"key20211117145015979_ref1-bib240","volume-title":"PROSPERO: International Prospective Register of Systematic Reviews","author":"National Institute for Health Research","year":"2019"},{"key":"key20211117145015979_ref1-bib241","volume-title":"Strings Attached: CADTH Database Search Filters","author":"Canadian Agency for Drugs and Technologies in Health","year":"2016"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2038087","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta25640\/hta25640.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2038087","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:38:41Z","timestamp":1692113921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta25640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":241,"journal-issue":{"issue":"64","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["10.3310\/hta25640"],"URL":"https:\/\/doi.org\/10.3310\/hta25640","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"3-2018","name":"contractual_start_date","label":"Contractual start date","group":{"name":"article_history","label":"Article History"}},{"value":"10-2019","name":"editorial_review_begun","label":"Editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"7-2020","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}